Perceptive is a trusted imaging core lab for oncology clinical trials, having supported over 1,800 studies and more than 300 regulatory approvals to date.
Learn about our expertise in:
Whether your study involves RECIST, Lugano, mRECIST, RANO or other oncology imaging endpoints, radioligand therapies, or complex clinical biomarker integration, our scalable medical imaging oncology services deliver the expertise and infrastructure needed to meet the highest data standards and regulatory rigor.
From Phase I oncology trials to pivotal registration studies, our imaging core lab supports every step of your imaging workflow. For trials exploring advanced endpoints, we offer cutting-edge image analysis capabilities, including radiomics and AI-powered pipelines, enabling deeper insights into tumor response and progression.
Imaging strategy and study designs are led by board-certified radiologists and oncology imaging experts who bring decades of experience in oncology clinical development and regulatory engagement.
We deliver the precision and flexibility you need, whether your study involves conventional CT and MRI scans or specialized imaging for novel mechanisms of action like radioligand therapies and antibody drug conjugates (ADC).
We support the whole range of oncology indications — including breast cancer, renal cell carcinoma, lung cancer, CNS tumors and hematologic malignancies — with tailored imaging strategies that reflect the nuances of each disease area.
Our proprietary, technology-enabled platform streamlines image quality control, reader performance monitoring, and data delivery — delivering greater insights to help inform confident decision making, faster.
With zero observations across FDA, EMA, and NMPA inspections over the past decade, our inspection readiness program and quality systems are proven to meet global regulatory expectations.
Whether your study is fast-tracked at the start or becomes accelerated later, trust Perceptive’s scalable operational model and global employees to deliver harmonized, 24/7 support that scales to meet timelines and drive your trial’s success.
Perceptive Imaging brings significant experience in solid tumor clinical trial imaging, supporting all phases of clinical development and helping sponsors meet global regulatory expectations, across both standard-of-care and advanced medical imaging.
Our scientific and operational teams work in lockstep to ensure imaging strategies are aligned with regulatory expectations from day one — reducing risk, accelerating timelines, and supporting breakthrough designations.
Contact us to discuss other capabilities not listed below, or other, emerging solutions for your study.
Our expertise includes, but is not limited to:
Vice President of Medical Services, a board-certified radiologist with over 25 years of experience in medical imaging and a recognized expert in imaging biomarkers across therapeutic areas.
A recognized authority in clinical trial imaging for more than 20 years and a co-author of both irRC and irRECIST. His leadership ensures that every imaging strategy is grounded in the latest science and regulatory expectations.
We’re pioneering radiopharmacuticals.
Multiple Myeloma Imaging, Leukemia Imaging, Lymphoma Imaging, and Myelofibrosis Imaging
Hematologic malignancy trial imaging is especially complex. Multiple Myeloma, Lymphoma, and Leukemia trials require not only clinical trial imaging, but also the integration of complex clinical data to support efficacy endpoints. And Myelofibrosis trials require multiple imaging modalities and specialized expertise to demonstrate treatment effect with confidence.
Having supported over 360 malignant hematology trials and 69 regulatory approvals, our imaging core lab services have been proven to meet these challenges head on. The result? You don’t have to worry about gaps or delays, and you gain confidence that your imaging data is high-quality and regulator-ready.
As trial complexity increases, so does the likelihood for things to go wrong – but not with Perceptive Imaging.
We have the people, processes, and infrastructure to keep your trial on track. Our integrated imaging and clinical data workflows are proven, scalable, regulator-aligned, and ready to meet the most complex trial needs.
Senior Medical Director and Head of Hemato-Oncology, with two decades of experience in clinical development and deep specialization in hematologic malignancies.
We provide comprehensive imaging services for oncology trials, including tumor response assessments (e.g. RECIST, mRECIST, RANO), radioligand therapy support, advanced image analysis (radiomics/AI), and biomarker integration across phases I to pivotal registration.
Perceptive maintains rigorous quality systems and inspection readiness programs with zero observations over the past decade in FDA, EMA, and NMPA inspections. We align imaging strategy and data workflows to global regulatory expectations from study planning through submission.
We support a wide range of solid tumors (e.g. lung, breast, colorectal, CNS, RCC) and hematologic malignancies (e.g. multiple myeloma, lymphoma, leukemia), using CT, MRI, PET, SPECT, bone scan, mammography, and more.
Yes. we have experience designing imaging strategies for advanced mechanisms like antibody-drug conjugates (ADCs), gene and cell therapies, and radioligand therapies, and incorporating advanced endpoints, dosimetry, and imaging biomarker integration.
Key differentiators include eadership by industry-recognized, therapeutically-aligned scientific experts, scalable global operations (including APAC presence), streamlined image QC and centralized platform, and deep experience across >1,800 trials and >300 regulatory approvals.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
